The Mexican consensus on the treatment of hepatitis C

Aiza-Haddad, I.; Ballesteros-Amozurrutia, A.; Borjas-Almaguer, Omar D.; Castillo-Barradas, M.; Castro-Narro, G.E.; Chávez-Tapia, Norberto C.; Chirino-Sprung, R.A.; Cisneros-Garza, L.E.; Dehesa-Violante, Margarita; Flores-Calderón, J.; Flores-Gaxiola, A.; García‐Juárez, Ignacio; González-Huezo, M.S.; González-Moreno, E.I.; Tijera, Fátima Higuera-de la; Kershenobich-Stalnikowitz, David; López-Méndez, Eric; Malé-Velázquez, R.; Marín-López, E; Mata‐Marín, José Antonio; Méndez-Sánchez, Nahúm; Monreal-Robles, Roberto; Moreno-Alcántar, R.; Muñoz-Espinosa, Linda E.; Navarro-Alvarez, S.; Pavía-Ruz, Noris; Pérez-Ríos, Alma Minerva; Poo-Ramírez, J.L.; Rizo-Robles, M.T.; Sánchez-Ávila, Juan Francisco; Sandoval-Salas, R.; Torre, Aldo; Torres-Ibarra, Rocio; Trejo-Estrada, R.; Velasco, J.A. Velarde-Ruiz; Wolpert-Barraza, Enrique; Bosques-Padilla, Francisco

doi:10.1016/j.rgmxen.2017.11.002

Cited by 2 publications

(2 citation statements)

References 217 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of CKD is significantly higher in HCV patients (9.6 vs. 5.1%) and, mainly in these patients, the development of CKD and end-stage renal disease occur in a shorter time; furthermore, a higher viral load has been described as an independent predictor of CKD [17]. Nowadays, there are many drugs to treat HCV satisfactorily; thus, it is a priority to make an early diagnosis and offer the proper treatment, removing this risk factor, in addition to the benefit of stopping the liver damage [20]. In this study, HCV coinfection showed to be a significant risk factor for CKD development (RR:3.8; p = 0.015 (univariate analysis), RR:5.6; p = 0.001 (multivariate analysis)).…”

Section: Discussionmentioning

confidence: 99%

Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort

et al. 2021

View full text Add to dashboard Cite

Background HIV subjects have several kidney pathologies, like HIV-associated nephropathy or antiretroviral therapy injury, among others. The global prevalence of Chronic Kidney Disease (CKD) is 8–16%; however, in HIV subjects, the prevalence varies between geographic regions (2–38%). The aim was to determine the prevalence of CKD and identify the associated risk factors. Methods A longitudinal descriptive study was carried out at the 'Hospital Civil de Guadalajara' Feb'18 – Jan'19. Basal clinical, demographic, opportunistic infections (OI), and laboratory data were obtained at months 0 and 3; inclusion criteria were ≥ 18 years old, naïve HIV + , urine albumin/creatinine ratio, serum creatinine & urine test, and signed informed consent. Descriptive and multiple logistic regression statistical analyses were made. Results One hundred twenty subjects were included; 92.5% were male, 33 ± 9.5 years, 60% consumed tobacco, 73% alcohol, and 59% some type of drug. The CKD prevalence was 15.8%. CKD patients had a higher risk of hepatitis C virus coinfection, Relative Risk (RR):5.9; HCV infection, RR:4.3; ≥ 30 years old, RR:3.9; C clinical-stage, RR:3.5; CD4+ T cells count < 200 cells/μL, RR: 2.4; and HIV-1 viral load ≥ 100,000 cop/mL, RR: 2.7. Conclusions Our study showed a higher CKD prevalence in patients with HIV; higher CKD development with coinfections as Hepatitis C Virus and Mycobacterium tuberculosis. The identification and prompt management of CKD and coinfections should be considered to avoid the progression and to delay renal replacement therapy as long as possible.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In Canada, the only DAA therapies approved for use in children (as of December 2019) are the combination of sofosbuvir and ledipasvir for children with HCV genotype 1 and the combination of glecaprevir and pibrentasvir for children with any genotype, but both are only approved for youth ages 12 to 17 years (119). In Mexico, available DAA therapies include daclatasvir, asunaprevir, simeprevir, sofosbuvir, and combination therapies with grazoprevir/elbasavir, ombitasvir/paritaprevir/ritonavir with dasabuvir (OBV/PTV/r/DSV), sofosbuvir/ledipasvir and grazeprevir/elbasvir, though many are not available for children under the age of 12 years (120).…”

Section: Treatment In Childrenmentioning

confidence: 99%

Hepatitis C in 2020

Leung

Squires

Jhaveri

et al. 2020

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

In 1989, a collaboration between the Centers for Disease Control (CDC) and a California biotechnology company identified the hepatitis C virus (HCV, formerly known as non-A, non-B hepatitis virus) as the causative agent in the epidemic of silent posttransfusion hepatitis resulting in cirrhosis. We now know that, the HCV genome is a 9.6 kb positive, single-stranded RNA. A single open reading frame encodes a 3011 amino acid residue polyprotein that undergoes proteolysis to yield 10 individual gene products, consisting of 3 structural proteins (core and envelope glycoproteins E1 and E2) and 7 nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B), which participate in posttranslational proteolytic processing and replication of HCV genetic material. Less than 25 years later, a new class of medications, known as direct-acting antivirals (DAAs) which target these proteins, were introduced to treat HCV infection. These highly effective antiviral agents are now approved for use in children as young as 3 years of age and have demonstrated sustained virologic responses exceeding 90% in most genotypes. Although tremendous scientific progress has been made, the incidence of acute HCV infections has increased by 4-fold since 2005, compounded in the last decade by a surge in opioid and intravenous drug use. Unfortunately, awareness of this deadly hepatotropic virus among members of the lay public remains limited. Patient education, advocacy, and counseling must, therefore, complement the availability of curative treatments against HCV infection if this virus is to be eradicated.

show abstract

The Mexican consensus on the treatment of hepatitis C

Cited by 2 publications

References 217 publications

Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort

Prevalence and risk factors of chronic kidney disease in an HIV positive Mexican cohort

Hepatitis C in 2020

Contact Info

Product

Resources

About